The Discovery Centre (DISC) in Cambridge, UK. (Credit: AstraZeneca)

‘A new era of growth’: As­traZeneca aims for $80B rev­enue, 20 new drugs by 2030

As­traZeneca on Tues­day morn­ing un­veiled its am­bi­tious plan to be one of the fastest grow­ing phar­ma com­pa­nies by the end of the decade.

In what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.